Crucially, many PTSPs were recurrent across samples (including at single-cell–clone resolution) and traced to cancer/immune genes such as MITF, DAPK1, and HLA-E; selected ligands were validated synthetically and shown to be immunogenic, settling earlier debates that had reported inflated prevalence yet preserving the key biological point: splicing creates shared, targetable sequences beyond the linear proteome (47). The gene discussed is HLA-E; the disease is cancer.